CRDF CARDIFF ONCOLOGY INC revenue, earnings and financials

For the quarter ended June 30, 2026, CARDIFF ONCOLOGY INC reported revenue of $104K (down 14.0% from a year earlier), net income of −$9.23M and diluted EPS of −$0.14; over the last four quarters revenue was $508K and net income $5.75M; for the fiscal year ended December 2025 revenue was $593K, down 13.2% on the year before.

CRDF annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $593K, gross profit n/a, operating income −$49.0M, net income −$45.9K (margin -7.7%), EPS −$0.69
• Fiscal year ended Dec 2024: revenue $683K, gross profit n/a, operating income −$48.7M, net income −$45.4K (margin -6.7%), EPS −$0.95
• Fiscal year ended Dec 2023: revenue $488K, gross profit n/a, operating income −$45.4M, net income −$41.4K (margin -8.5%), EPS −$0.93
• Fiscal year ended Dec 2022: revenue $386K, gross profit n/a, operating income −$39.9M, net income −$38.7M (margin -10026.9%), EPS −$0.89
• Fiscal year ended Dec 2021: revenue $359K, gross profit n/a, operating income −$28.9M, net income −$28.3M (margin -7880.5%), EPS −$0.73

CRDF quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $104K (down 14.0% year over year), net income −$9.23M, EPS −$0.14
• Quarter ended Mar 31, 2026: revenue $41.0K (down 62.4% year over year), net income −$12.3M, EPS −$0.18
• Quarter ended Dec 31, 2025 (from the annual report): revenue $243K (up 62.0% year over year), net income $38.6M, EPS −$0.11
• Quarter ended Sep 30, 2025: revenue $120K (down 27.3% year over year), net income −$11.3M, EPS −$0.17
• Quarter ended Jun 30, 2025: revenue $121K (down 25.8% year over year), net income −$13.9M, EPS −$0.21
• Quarter ended Mar 31, 2025: revenue $109K (down 46.8% year over year), net income −$13.4M, EPS −$0.20
• Quarter ended Dec 31, 2024 (from the annual report): revenue $150K (down 3.8% year over year), net income $33.6M, EPS −$0.22
• Quarter ended Sep 30, 2024: revenue $165K (up 17.0% year over year), net income −$11.9M, EPS −$0.25
• Quarter ended Jun 30, 2024: revenue $163K (up 50.9% year over year), net income −$11.8M, EPS −$0.26
• Quarter ended Mar 31, 2024: revenue $205K (up 147.0% year over year), net income −$10.0M, EPS −$0.22
• Quarter ended Dec 31, 2023 (from the annual report): revenue $156K (up 21.9% year over year), net income $32.1M, EPS −$0.21
• Quarter ended Sep 30, 2023: revenue $141K (up 51.6% year over year), net income −$9.73M, EPS −$0.22
• Quarter ended Jun 30, 2023: revenue $108K (up 18.7% year over year), net income −$11.2M, EPS −$0.25
• Quarter ended Mar 31, 2023: revenue $83.0K (up 12.2% year over year), net income −$11.2M, EPS −$0.25
• Quarter ended Dec 31, 2022 (from the annual report): revenue $128K (down 3.8% year over year), net income −$8.70M, EPS −$0.20
• Quarter ended Sep 30, 2022: revenue $93.0K (up 8.1% year over year), net income −$8.57M, EPS −$0.20
• Quarter ended Jun 30, 2022: revenue $91.0K (up 33.8% year over year), net income −$10.4M, EPS −$0.24
• Quarter ended Mar 31, 2022: revenue $74.0K (up 2.8% year over year), net income −$11.0M, EPS −$0.25
• Quarter ended Dec 31, 2021 (from the annual report): revenue $133K, net income −$9.44M, EPS −$0.25
• Quarter ended Sep 30, 2021: revenue $86.0K, net income −$6.91M, EPS −$0.17

CRDF cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$37.9M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$37.7M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$30.9M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$33.8M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$23.0M, share buybacks n/a

CRDF balance sheet

• Jun 30, 2026: cash $9.20M, total assets $37.3M, total liabilities $10.8M, shareholders' equity $26.5M
• Mar 31, 2026: cash $8.54M, total assets $49.2M, total liabilities $14.5M, shareholders' equity $34.7M
• Dec 31, 2025: cash $17.5M, total assets $61.9M, total liabilities $16.5M, shareholders' equity $45.4M
• Sep 30, 2025: cash $10.1M, total assets $63.8M, total liabilities $15.0M, shareholders' equity $48.8M
• Jun 30, 2025: cash $10.8M, total assets $75.7M, total liabilities $17.1M, shareholders' equity $58.6M
• Mar 31, 2025: cash $24.1M, total assets $84.8M, total liabilities $13.9M, shareholders' equity $70.9M
• Dec 31, 2024: cash $51.5M, total assets $97.2M, total liabilities $14.2M, shareholders' equity $82.9M
• Sep 30, 2024: cash $13.0M, total assets $62.9M, total liabilities $13.5M, shareholders' equity $49.4M

What is CRDF's revenue?

CARDIFF ONCOLOGY INC reported $508K of revenue over its last four quarters, through June 30, 2026.

Is CRDF profitable?

Yes. CARDIFF ONCOLOGY INC earned $5.75M over the last four quarters.

What is CRDF's EPS?

Diluted earnings per share over the last four quarters were −$0.60; −$0.14 in the latest quarter.

CRDF ownership and insider trades · All stocks